Rituximab in the Treatment of Graves' Disease

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Aim:

In a phase II pilot study encompassing 20 patients with Graves' disease to evaluate the effect of rituximab:

1. Biochemically as assessed by markers of disease activity ( free T4, free T3, TSH, TSH-receptor antibodies, anti-TPO)

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Odense University Hospital
• Treatments: Methimazole; Rituximab; Vaccines

Criteria

Inclusion Criteria:

• Graves´ disease

• Adequate anticonception in women.

Exclusion Criteria:

• Performance status >2

• Previous rituximab treatment

• Immunosuppressive treatment

• Serious concomitant disease

• Active infections

• Pregnancy / breast feeding.